343 related articles for article (PubMed ID: 19276677)
1. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.
Wheeler DL; Iida M; Kruser TJ; Nechrebecki MM; Dunn EF; Armstrong EA; Huang S; Harari PM
Cancer Biol Ther; 2009 Apr; 8(8):696-703. PubMed ID: 19276677
[TBL] [Abstract][Full Text] [Related]
2. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.
Li C; Iida M; Dunn EF; Wheeler DL
Radiother Oncol; 2010 Nov; 97(2):330-7. PubMed ID: 20667610
[TBL] [Abstract][Full Text] [Related]
5. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
Brand TM; Iida M; Corrigan KL; Braverman CM; Coan JP; Flanigan BG; Stein AP; Salgia R; Rolff J; Kimple RJ; Wheeler DL
Sci Signal; 2017 Jan; 10(460):. PubMed ID: 28049763
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
[TBL] [Abstract][Full Text] [Related]
7. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
8. Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.
Iida M; Brand TM; Campbell DA; Li C; Wheeler DL
Oncogene; 2013 Feb; 32(6):759-67. PubMed ID: 22430206
[TBL] [Abstract][Full Text] [Related]
9. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
Yoshida T; Okamoto I; Okamoto W; Hatashita E; Yamada Y; Kuwata K; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Cancer Sci; 2010 Jan; 101(1):167-72. PubMed ID: 19804422
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.
Wheeler DL; Huang S; Kruser TJ; Nechrebecki MM; Armstrong EA; Benavente S; Gondi V; Hsu KT; Harari PM
Oncogene; 2008 Jun; 27(28):3944-56. PubMed ID: 18297114
[TBL] [Abstract][Full Text] [Related]
11. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
Lin YC; Wu MH; Wei TT; Chuang SH; Chen KF; Cheng AL; Chen CC
Neoplasia; 2012 Jun; 14(6):463-75. PubMed ID: 22787428
[TBL] [Abstract][Full Text] [Related]
12. Nuclear EGFR contributes to acquired resistance to cetuximab.
Li C; Iida M; Dunn EF; Ghia AJ; Wheeler DL
Oncogene; 2009 Oct; 28(43):3801-13. PubMed ID: 19684613
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.
Song L; Morris M; Bagui T; Lee FY; Jove R; Haura EB
Cancer Res; 2006 Jun; 66(11):5542-8. PubMed ID: 16740687
[TBL] [Abstract][Full Text] [Related]
14. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
[TBL] [Abstract][Full Text] [Related]
15. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
Iida M; Bahrar H; Brand TM; Pearson HE; Coan JP; Orbuch RA; Flanigan BG; Swick AD; Prabakaran PJ; Lantto J; Horak ID; Kragh M; Salgia R; Kimple RJ; Wheeler DL
Mol Cancer Ther; 2016 Sep; 15(9):2175-86. PubMed ID: 27422810
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.
Johnson FM; Bekele BN; Feng L; Wistuba I; Tang XM; Tran HT; Erasmus JJ; Hwang LL; Takebe N; Blumenschein GR; Lippman SM; Stewart DJ
J Clin Oncol; 2010 Oct; 28(30):4609-15. PubMed ID: 20855820
[TBL] [Abstract][Full Text] [Related]
17. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Wheler J; Falchook G; Tsimberidou AM; Hong D; Naing A; Piha-Paul S; Chen SS; Heymach J; Fu S; Stephen B; Fok JY; Janku F; Kurzrock R
Oncotarget; 2013 May; 4(5):772-84. PubMed ID: 23800712
[TBL] [Abstract][Full Text] [Related]
18. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
Wheeler SE; Morariu EM; Bednash JS; Otte CG; Seethala RR; Chiosea SI; Grandis JR
Clin Cancer Res; 2012 May; 18(10):2850-60. PubMed ID: 22490227
[TBL] [Abstract][Full Text] [Related]
19. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
[TBL] [Abstract][Full Text] [Related]
20. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
